Effects of a combination of puerarin, baicalin and berberine on the expression of proliferator‑activated receptor-γ and insulin receptor in a rat model of nonalcoholic fatty liver disease

Experimental and Therapeutic Medicine

Volumn 11, Issue 1, 2016, Pages 183-190

  Zhao, Weihan ^a   Liu, Lijuan ^a   Wang, Yunliang ^a   Mao, Tangyou ^a   Li, Junxiang ^a  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Baicalin; Berberine; Insulin receptor; Non alcoholic fatty liver disease; Proliferator activated receptor ; Puerarin

Indexed keywords

BAICALIN; BERBERINE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; INSULIN RECEPTOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PUERARIN; ROSIGLITAZONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DRUG DOSE COMPARISON; ENZYME LINKED IMMUNOSORBENT ASSAY; LIVER FIBROSIS; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

EID: 84949447769     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2846     Document Type: Article

References (40)

1. Marchesini G and Marzocchi R: Metabolic syndrome and NASH. Clin Liver Dis 11: 105-117, ix 2007.
2. Fabbrini E, Sullivan S and Klein S: Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic and clinical implications. Hepatology 51: 679-689, 2010.
3. Song HY, Zhang L, Pan JL, Yang LL and Ji G: Bioactivity of five components of Chinese herbal formula Jiangzhi granules against hepatocellular steatosis. J Integr Med 11: 262-268, 2013.
4. Stein LL, Dong MH and Loomba R: Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status. Adv Ther 26: 893-907, 2009.
5. Sun L and Lü SZ: Association between non-alcoholic fatty liver disease and coronary artery disease severity. Chin Med J (Engl) 124: 867-872, 2011.
6. Zhao JS, Zhu FS, Liu S, Yang CQ and Chen XM: Pioglitazone ameliorates nonalcoholic steatohepatitis by down-regulating hepatic nuclear factor-kappa B and cyclooxygenases-2 expression in rats. Chin Med J (Engl) 125: 2316-2321, 2012.
7. Zhao CY, Jiang LL, Li L, Deng ZJ, Liang BL and Li JM: Peroxisome proliferator activated receptor-gamma in pathogenesis of experimental fatty liver disease. World J Gastroenterol 10: 1329-1332, 2004.
8. Nan YM, Fu N, Wu WJ, Liang BL, Wang RQ, Zhao SX, Zhao JM and Yu J: Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. Scand J Gastroenterol 44: 358-365, 2009.
9. Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, Borg B, Loomba R, Liang TJ and Premkumar A: The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 46: 424-429, 2007.
10. Chiu SL and Cline HT: Insulin receptor signaling in the development of neuronal structure and function. Neural Dev 5: 7, 2010.
11. Zhang Q, Xiao XH, Li M, Li WH, Yu M, Zhang HB, Ping F, Wang ZX and Zheng J: Chromium-containing traditional Chinese medicine, Tianmai Xiaoke Tablet improves blood glucose through activating insulin-signaling pathway and inhibiting PTP1B and PCK2 in diabetic rats. J Integr Med 12: 162-170, 2014.
12. Samuel VT and Shulman GI: Integrating mechanisms for insulin resistance: Common threads and missing links. Cell 148: 852-871, 2012.
13. Mohammadi A, Gholamhoseinian A and Fallah H: Zataria multiflora increases insulin sensitivity and PPAR-γ gene expression in high fructose fed insulin resistant rats. Iran J Basic Med Sci 17: 263-270, 2014.
14. Rani S and O’Driscoll L: Analysis of changes in phosphorylation of receptor tyrosine kinases: Antibody arrays. Methods Mol Biol 1233: 15-23, 2015.
15. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, et al: A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39: 188-196, 2004.
16. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, et al: Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27: 256-263, 2004.
17. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR and Fonseca VA: Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 134: 61-71, 2001.
18. Wang WJ: Enhancing the treatment of metabolic syndrome with integrative medicine. J Integr Med 11: 153-156, 2013.
19. Yao Z, Zhang L and Ji G: Efficacy of polyphenolic ingredients of Chinese herbs in treating dyslipidemia of metabolic syndromes. J Integr Med 12: 135-146, 2014.
20. Wang Y, Li J, Zhuge L, Su D, Yang M, Tao S and Li J: Comparison between the efficacies of curcumin and puerarin in C57BL/6 mice with steatohepatitis induced by a methionine-and choline-deficient diet. Exp Ther Med 7: 663-668, 2014.
21. Guo HX, Liu DH, Ma Y, Liu JF, Wang Y, Du ZY, Wang X, Shen JK and Peng HL: Long-term baicalin administration ameliorates metabolic disorders and hepatic steatosis in rats given a high-fat diet. Acta Pharmacol Sin 30: 1505-1512, 2009.
22. Chang X, Yan H, Fei J, Jiang M, Zhu H, Lu D and Gao X: Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats. J Lipid Res 51: 2504-2515, 2010.
23. Cui W, Li X, Zhou S and Weng J: Investigation on process parameters of electrospinning system through orthogonal experimental design. J Appl Polym Sci 103, 3105-3112, 2007.
24. Khan F, Choong WL, Du Q and Jovanovi'c A: Real-time RT-PCR Ct values for blood GAPDH correlate with measures of vascular endothelial function in humans. Clin Transl Sci 6: 481-484, 2013.
25. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC and McCullough AJ: Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 116: 1413-1419, 1999.
26. Adams LA and Angulo P: Treatment of non-alcoholic fatty liver disease. Postgrad Med J 82: 315-322, 2006.
27. Day CP and James OF: Steatohepatitis: A tale of two hits? Gastroenterology 114: 842-845, 1998.
28. Postic C and Girard J: Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: Lessons from genetically engineered mice. J Clin Invest 118: 829-838, 2008.
29. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP and Hsueh WA: Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 101: 1311-1318, 2000.
30. Harrison SA: Thiazolidinedione therapy for nonalcoholic steatohepatitis: Go, stop, or proceed with caution? Hepatology 51: 366-369, 2010.
31. Nan YM, Fu N, Wu WJ, Liang BL, Wang RQ, Zhao SX, Zhao JM and Yu J: Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. Scand J Gastroenterol 44: 358-365, 2009.
32. Cheatham B and Kahn CR: Cysteine 647 in the insulin receptor is required for normal covalent interaction between alpha-andbeta-subunits and signal transduction. J Biol Chem 267: 7108-7115, 1992.
33. Seino S and Bell GI: Alternative splicing of human insulin receptor messenger RNA. Biochem Biophys Res Commun 159: 312-316, 1989.
34. El-Bassossy HM, Abo-Warda SM and Fahmy A: Chrysin and luteolin alleviate vascular complications associated with insulin resistance mainly through PPAR-γ activation. Am J Chin Med 42: 1153-1167, 2014.
35. Shamsi BH, Ma C, Naqvi S and Xiao Y: Effects of pioglitazone mediated activation of PPAR-γ on CIDEC and obesity related changes in mice. PLoS One 9: e106992, 2014.
36. Wang RC and Jiang DM: PPAR-γ agonist pioglitazone affects rat gouty arthritis by regulating cytokines. Genet Mol Res 13: 6577-6781, 2014.
37. Seeff LB, Lindsay KL, Bacon BR, Kresina TF and Hoofnagle JH: Complementary and alternative medicine in chronic liver disease. Hepatology 34: 595-603, 2001.
38. Liu RJ, Zhang YW, Wen CW and Tang J: Study on the design and analysis methods of orthogonal experiment. Exp Technol and Manage 27: 52-55, 2010.
39. Silva RN, Bueno PG, Avó LR, Nonaka KO, Selistre-Araújo HS and Leal AM: Effect of physical training on liver expression of activin A and follistatin in a nonalcoholic fatty liver disease model in rats. Braz J Med Biol Res 47: 746-752, 2014.
40. Kucera O and Cervinkova Z: Experimental models of non-alcoholic fatty liver disease in rats. World J Gastroenterol 20: 8364-8376, 2014.